Oncology Business Management | Specialty

Chemotherapy Parity Laws Ignore Cost, Quality Question

January 2nd 2015

With the FDA approval of several oral chemotherapy agents, the cost of medications to treat cancer is increasing rapidly. To control costs, legislators, patient advocates, and physicians have pushed for oral chemotherapy parity laws.

"Perverse Incentives" Add Costs to Dying Patients

December 29th 2014

Sweeping changes to the way America delivers care at the end of life would better serve patients and their families, while achieving the goals sought in the Affordable Care Act (ACA) of better health, cost savings, and especially patient satisfaction

There's No Place Like a Medical Home: Premier Medical Group Focuses on Full-scale Patient-Centered Care

December 28th 2014

It's not uncommon for a business to use a superlative in its name, but Premier Medical Group in Poughkeepsie, NY, truly lives up to its moniker.

Will Oncology Care in the Future Look Vastly Different From Today?

December 26th 2014

It is always fun to try to predict the future. Invariably you will be wrong.

Collaboration in Groups Improves Care, Averts Pay Cuts

December 24th 2014

Urologists who are members of LUGPA are doing the right thing by being part of large group practices.

FDA Approves Nivolumab for Advanced Melanoma

December 22nd 2014

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

Dreams of Opening a Solo Practice Dwindling Says Survey of Future Docs

December 22nd 2014

Only 10% of current medical students aspire to open up shop as a solo practitioner-a 50% drop since 2008. Last year, 17% of students surveyed said that solo practice was a consideration. On the other hand, those students who anticipate seeking employment with a large group practice or hospital has risen to 73%, as compared with 70% last year.

FDA Approves Olaparib for Advanced Ovarian Cancer

December 19th 2014

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.

Clinical Pathways Can Lead to Cost Savings, Better Care

December 18th 2014

Several initiatives that have a dramatic impact on healthcare today were born during that time–managed care, transitioning away from inpatient care toward outpatient care, and the introduction of clinical pathways.

Final Thoughts on Improving Prostate Cancer Care

December 17th 2014

Integrating a Medical Oncologist Into Urology Practices

December 17th 2014

Combination Strategies Explored in CRPC

December 17th 2014

Integrating Radium-223 Into Clinical Practice

December 17th 2014

Providing Optimal Care for Prostate Cancer

December 17th 2014

Data: The New Currency in Healthcare Improvement

December 17th 2014

Integrating Dispensing Pharmacy Services Into a Urology Group

December 17th 2014

Multiparametric MRI Biopsies: Poised for Widespread Adoption?

December 17th 2014

Multiparametric MRI for Detecting Prostate Cancer

December 17th 2014

Large Groups Are Positioned Well in New Healthcare Arena

December 17th 2014

While Laszewski said the Affordable Care Act (ACA), which is driving many of the changes, may end up being altered, he doesn't expect the program to be disbanded due to the political shift in legislative power.

FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors

December 16th 2014

The FDA has approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.